In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model
暂无分享,去创建一个
[1] F. Hock. Drug Discovery and Evaluation: Pharmacological Assays , 2016, Springer International Publishing.
[2] S. Popov,et al. Anti-inflammatory activity of low and high methoxylated citrus pectins , 2013 .
[3] M. Fan,et al. Consumption of guar gum and retrograded high-amylose corn resistant starch increases IL-10 abundance without affecting pro-inflammatory cytokines in the colon of pigs fed a high-fat diet. , 2012, Journal of animal science.
[4] S. Popov,et al. Anti-inflammatory activity of pectins and their galacturonan backbone , 2011, Russian Journal of Bioorganic Chemistry.
[5] Tejal J Shah,et al. Polysaccharides: a targeting strategy for colonic drug delivery , 2011, Expert opinion on drug delivery.
[6] D. Chu,et al. Hydrolyzed guar gum decreases postprandial blood glucose and glucose absorption in the rat small intestine. , 2009, Nutrition research.
[7] S. Popov,et al. Antiinflammatory activity of the pectic polysaccharide from Comarum palustre. , 2005, Fitoterapia.
[8] L. Fitzpatrick,et al. Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat , 1990, Agents and Actions.
[9] B. Youan,et al. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[10] D. Parkins,et al. Pectin/Ethylcellulose Film Coating Formulations for Colonic Drug Delivery , 1996, Pharmaceutical Research.
[11] Jindřich Kopeček,et al. Hydrogels for Site-Specific Drug Delivery to the Colon: In Vitro and in Vivo Degradation , 1992, Pharmaceutical Research.
[12] M. K. Chourasia,et al. Pharmaceutical approaches to colon targeted drug delivery systems. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[13] Libo Yang,et al. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. , 2002, International journal of pharmaceutics.
[14] V. Satyanarayana,et al. Guar gum as a carrier for colon specific delivery; influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets. , 2001, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[15] V. Sinha,et al. Polysaccharides in colon-specific drug delivery. , 2001, International journal of pharmaceutics.
[16] T. Fujita,et al. Validation of a Pharmacokinetic Model of Colon‐specific Drug Delivery and the Therapeutic Effects of Chitosan Capsules Containing 5‐Aminosalicylic Acid on 2,4,6‐Trinitrobenzenesulphonic Acid‐induced Colitis in Rats , 1999, The Journal of pharmacy and pharmacology.
[17] S. Satyanarayana,et al. In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[18] L. Vervoort,et al. Colonic drug targeting. , 1998, Journal of drug targeting.
[19] S. Bondesen,et al. Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. , 1997, Pharmacology & toxicology.
[20] H. G. Vogel. Drug Discovery and Evaluation: Pharmacological Assays , 1997 .
[21] R. Fedorak,et al. Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. , 1995, Gastroenterology.
[22] K. Antonin,et al. Colonic absorption of human calcitonin in man. , 1992, Clinical science.
[23] T. Wöhrmann,et al. Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease , 1992, Mediators of inflammation.
[24] A. Rubinstein. Microbially controlled drug delivery to the colon , 1990, Biopharmaceutics & drug disposition.
[25] J. Wallace,et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.
[26] G. Macfarlane,et al. Significance of microflora in proteolysis in the colon , 1989, Applied and environmental microbiology.
[27] D. Neckers,et al. A new approach to the oral administration of insulin and other peptide drugs. , 1986, Science.
[28] G. Friedman. Sulfasalazine and new analogues. , 1986, The American journal of gastroenterology.
[29] U. Klotz,et al. Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid , 1985, Clinical pharmacokinetics.
[30] W. Stenson,et al. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. , 1984, Gastroenterology.
[31] D. Priebat,et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.
[32] J. Travis,et al. Isolation and properties of human neutrophil myeloperoxidase. , 1981, Biochemistry.
[33] D. Roos,et al. Characterization and quantification of the peroxidase in human monocytes. , 1978, Biochimica et biophysica acta.
[34] S. Truelove,et al. AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.
[35] B. MacPherson,et al. Experimental colitis. , 1976, Digestion.
[36] 野口 照久. 「Evaluation of Drug Activities: Pharmacometrics」, Vol. 1, 15×23cm判, 456頁, 5,700円, Vol.2 438頁, 5,400円, Academic Press, D. R. Laurence & A. L. Bacharach編 , 1965 .